Comments on: Velcade-Dexamethasone Combination Regimen Increases Survival In Newly Diagnosed High Risk Myeloma Patients (ASH 2009) http://www.myelomabeacon.com/news/2009/12/05/velcade-dexamethasone-combination-regimen-increases-survival-in-newly-diagnosed-high-risk-myeloma-patients-ash-2009/ The Myeloma Beacon provides extensive news, articles, and directories related to multiple myeloma. Its mission is to be the leading Internet resource for multiple myeloma patients, their families, and others interested in multiple myeloma. Fri, 30 Jul 2010 22:08:42 -0400 hourly 1 By: Sidney Hider http://www.myelomabeacon.com/news/2009/12/05/velcade-dexamethasone-combination-regimen-increases-survival-in-newly-diagnosed-high-risk-myeloma-patients-ash-2009/comment-page-1/#comment-1645 Sidney Hider Tue, 08 Dec 2009 23:19:34 +0000 http://www.myelomabeacon.com/?p=8814#comment-1645 Funmi, Thank you for the prompt reply. The Myeloma Beacon never lets me down. Sid Funmi,
Thank you for the prompt reply.
The Myeloma Beacon never lets me down.
Sid

]]> By: Funmi Adewale http://www.myelomabeacon.com/news/2009/12/05/velcade-dexamethasone-combination-regimen-increases-survival-in-newly-diagnosed-high-risk-myeloma-patients-ash-2009/comment-page-1/#comment-1637 Funmi Adewale Tue, 08 Dec 2009 04:41:11 +0000 http://www.myelomabeacon.com/?p=8814#comment-1637 Hi Sid, The ASH abstract didn’t provide any side effect information, but I looked up an author (Harousseau, JL) it referenced and found a phase 2 trial published in 2006 evaluating the VD regimen on 52 patients. Side effects included: mild to moderate gastrointestinal symptoms, peripheral neuropathy, fatigue, blood clotting in the veins, and abnormal blood cell counts. Five patients (10 percent) experienced grade 3 infections, and seven patients (14 percent) experienced grade 2-3 peripheral neuropathy. Researchers concluded that the therapy was “well tolerated.” However, since the ASH abstract doesn’t specify what dose of VD was administered, I can’t be sure that exactly the same regimen was used in both studies. Here's a link to the 2006 trial abstract: http://www.haematologica.org/cgi/content/abstract/91/11/1498 Hope this helps, Funmi Hi Sid,

The ASH abstract didn’t provide any side effect information, but I looked up an author (Harousseau, JL) it referenced and found a phase 2 trial published in 2006 evaluating the VD regimen on 52 patients.

Side effects included: mild to moderate gastrointestinal symptoms, peripheral neuropathy, fatigue, blood clotting in the veins, and abnormal blood cell counts. Five patients (10 percent) experienced grade 3 infections, and seven patients (14 percent) experienced grade 2-3 peripheral neuropathy.

Researchers concluded that the therapy was “well tolerated.” However, since the ASH abstract doesn’t specify what dose of VD was administered, I can’t be sure that exactly the same regimen was used in both studies. Here’s a link to the 2006 trial abstract: http://www.haematologica.org/cgi/content/abstract/91/11/1498

Hope this helps,
Funmi

]]> By: Sidney Hider http://www.myelomabeacon.com/news/2009/12/05/velcade-dexamethasone-combination-regimen-increases-survival-in-newly-diagnosed-high-risk-myeloma-patients-ash-2009/comment-page-1/#comment-1631 Sidney Hider Tue, 08 Dec 2009 00:04:48 +0000 http://www.myelomabeacon.com/?p=8814#comment-1631 On first reading this is good news, an increase in myeloma survival. But what about the side effects? On first reading this is good news, an increase in myeloma survival.
But what about the side effects?

]]>